Maturation signatures of conventional dendritic cell subtypes in COVID-19 suggest direct viral sensing.
COVID-19
dendritic cells
single cell transcriptomics
Journal
European journal of immunology
ISSN: 1521-4141
Titre abrégé: Eur J Immunol
Pays: Germany
ID NLM: 1273201
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
09
06
2021
received:
12
04
2021
accepted:
29
07
2021
pubmed:
2
8
2021
medline:
15
1
2022
entrez:
1
8
2021
Statut:
ppublish
Résumé
Growing evidence suggests that conventional dendritic cells (cDCs) undergo aberrant maturation in COVID-19, which negatively affects T-cell activation. The presence of effector T cells in patients with mild disease and dysfunctional T cells in severely ill patients suggests that adequate T-cell responses limit disease severity. Understanding how cDCs cope with SARS-CoV-2 can help elucidate how protective immune responses are generated. Here, we report that cDC2 subtypes exhibit similar infection-induced gene signatures, with the upregulation of IFN-stimulated genes and IL-6 signaling pathways. Furthermore, comparison of cDCs between patients with severe and mild disease showed severely ill patients to exhibit profound downregulation of genes encoding molecules involved in antigen presentation, such as MHCII, TAP, and costimulatory proteins, whereas we observed the opposite for proinflammatory molecules, such as complement and coagulation factors. Thus, as disease severity increases, cDC2s exhibit enhanced inflammatory properties and lose antigen presentation capacity. Moreover, DC3s showed upregulation of anti-apoptotic genes and accumulated during infection. Direct exposure of cDC2s to the virus in vitro recapitulated the activation profile observed in vivo. Our findings suggest that SARS-CoV-2 interacts directly with cDC2s and implements an efficient immune escape mechanism that correlates with disease severity by downregulating crucial molecules required for T-cell activation.
Identifiants
pubmed: 34333764
doi: 10.1002/eji.202149298
pmc: PMC8420462
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
109-122Subventions
Organisme : Fondazione Cariplo (INNATE-CoV), Fondazione Veronesi (FRACOVID), AIRC
ID : IG 2019Id.23512
Organisme : Fondazione Regionale per la Ricerca Biomedica, FRRB
ID : IANG-CRC - CP2_12/2018
Organisme : Ministero della Salute, Ricerca Finalizzata
ID : RF-2018-12367072
Informations de copyright
© 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Science. 2017 Jun 9;356(6342):
pubmed: 28473638
J Clin Invest. 2020 Dec 1;130(12):6290-6300
pubmed: 32784290
Cell Res. 2021 Mar;31(3):272-290
pubmed: 33473155
Immunity. 2020 Jul 14;53(1):19-25
pubmed: 32610079
Virology. 2003 Jan 5;305(1):115-23
pubmed: 12504546
Science. 2020 Sep 4;369(6508):1210-1220
pubmed: 32788292
Proc Natl Acad Sci U S A. 2020 Oct 20;117(42):26328-26339
pubmed: 33020261
Immunity. 2019 Sep 17;51(3):573-589.e8
pubmed: 31474513
Nat Med. 2020 Mar;26(3):333-340
pubmed: 32066974
Nat Commun. 2020 Jul 6;11(1):3434
pubmed: 32632085
Cancer Res. 2016 Aug 1;76(15):4332-46
pubmed: 27325645
Nat Rev Immunol. 2019 Feb;19(2):89-103
pubmed: 30464294
J Leukoc Biol. 2017 Jan;101(1):39-52
pubmed: 27793959
Proc Natl Acad Sci U S A. 2021 Feb 9;118(6):
pubmed: 33479167
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
Annu Rev Immunol. 2021 Apr 26;39:131-166
pubmed: 33481643
Genome Biol. 2019 Dec 23;20(1):296
pubmed: 31870423
Front Immunol. 2017 Oct 23;8:1350
pubmed: 29109727
Nat Methods. 2019 Dec;16(12):1289-1296
pubmed: 31740819
Cell Rep. 2021 Feb 9;34(6):108728
pubmed: 33516277
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Blood. 2013 Aug 8;122(6):932-42
pubmed: 23794066
Nat Immunol. 2021 Feb;22(2):140-153
pubmed: 33349708
J Clin Invest. 2018 May 1;128(5):1720-1723
pubmed: 29629898
J Exp Med. 2010 Jun 7;207(6):1247-60
pubmed: 20479116
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5215-20
pubmed: 10220446
Bioinformatics. 2020 Feb 15;36(4):1150-1158
pubmed: 31501871
J Immunol. 2014 Nov 15;193(10):4914-4923
pubmed: 25288570
Nat Rev Rheumatol. 2020 Oct;16(10):581-589
pubmed: 32733003
Immunity. 2020 Aug 18;53(2):335-352.e8
pubmed: 32610077
Blood. 2008 Aug 15;112(4):1299-307
pubmed: 18541725
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Nat Immunol. 2014 Feb;15(2):195-204
pubmed: 24336226
Nat Rev Immunol. 2021 Feb;21(2):101-115
pubmed: 32908299
J Exp Med. 1999 Oct 18;190(8):1155-64
pubmed: 10523613
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nat Med. 2020 Oct;26(10):1623-1635
pubmed: 32807934
Eur J Immunol. 2022 Jan;52(1):109-122
pubmed: 34333764
J Infect Dis. 2021 Mar 3;223(5):785-795
pubmed: 33277988
Immunity. 2021 Jun 8;54(6):1304-1319.e9
pubmed: 34048708
Am J Transplant. 2014 May;14(5):1021-1031
pubmed: 24731243
Front Cell Infect Microbiol. 2013 Jul 24;3:32
pubmed: 23898465
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
Eur J Immunol. 2019 Oct;49(10):1457-1973
pubmed: 31633216
Cell. 2020 Sep 17;182(6):1419-1440.e23
pubmed: 32810438
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
Immunity. 2020 Oct 13;53(4):864-877.e5
pubmed: 32791036
Immunity. 2016 Sep 20;45(3):669-684
pubmed: 27637149
Immunity. 2020 Aug 18;53(2):353-370.e8
pubmed: 32735845
mBio. 2017 Oct 3;8(5):
pubmed: 28974616